QuidelOrtho Corporation QDEL

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Those leading the charge have not only realized strong financial performance but also propelled the broader industry’s returns as healthcare stocks have gained 38% over the past six months while the S&P 500 was up 16.9%.

QuidelOrtho Corporation (Nasdaq: QDEL), a global leader in in vitro diagnostics, is proud to share episode 61 of its Science Bytes podcast, highlighting key insights about lowering sepsis rates in the emergency room. Sepsis remains a leading cause of death in the U.S. Barriers to diagnosis lead to organ failure and higher mortality rates.

A number of stocks fell in the afternoon session after sentiment in the healthcare sector weakened, as the Centers for Medicare and Medicaid Services moved to cancel Affordable Care Act coverage for roughly 760,000 people and claw back billions in subsidies.

The global point-of-care diagnostics market is projected to grow from USD 20.63 billion in 2026 to USD 31.46 billion by 2031, at an 8.8% CAGR. Growth is driven by demand for rapid, accurate and decentralized testing, alongside advances in molecular diagnostics, microfluidics, multiplex assays and portable analyzers. Biochemistry holds the largest technology share, while molecular diagnostics and infectious disease testing are set for strong growth. Clinical laboratories lead by end user, and Nor

Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However, investors should remain vigilant as some may still have unproven business models, leaving them vulnerable to the ebbs and flows of the broader market.

QuidelOrtho Corporation (Nasdaq: QDEL), a leading global provider of diagnostic solutions, has released episode 60 of its Science Bytes podcast, featuring highlights from the 2026 Association for Diagnostics and Laboratory Medicine (ADLM) Annual Conference.

The Russell 2000 (^RUT) is packed with potential breakout stocks, thanks to its focus on smaller companies with high growth potential. However, smaller size also means these businesses often lack the resilience and financial flexibility of large-cap firms, making careful selection crucial.

Unprofitable companies face headwinds as they struggle to keep operating expenses under control. Some may be investing heavily, but the majority fail to convert spending into sustainable growth.

In early August 2026, QuidelOrtho reported second-quarter 2026 results showing sales of US$630.9 million and a net loss of US$92.9 million, alongside narrower losses per share than a year earlier. However, for the first half of 2026, sales eased to US$1.25 billion and the company reduced its full-year revenue outlook to US$2.52–2.60 billion, highlighting softer expectations despite improving losses. With QuidelOrtho lowering its full-year 2026 revenue guidance, we’ll now examine how this...

The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how QuidelOrtho (NASDAQ:QDEL) and the rest of the healthcare equipment and supplies stocks fared in Q2.

QuidelOrtho’s second quarter results were met with a negative market reaction, reflecting investor concern over significant challenges in key markets. While management pointed to solid demand in North America and strong commercial execution in regions like Japan and Latin America, CEO Brian J. Blaser cited a “softer respiratory environment” and pronounced weakness in China as primary factors impacting performance. The company’s leadership was notably cautious, highlighting that China revenue fel

The sharp reset in QuidelOrtho’s fair value estimate from US$20.50 to US$12.00 per share sits alongside analyst price targets that now cluster around the US$12 to US$18 range. Recent research has become more divided, with some firms lifting targets while holding Neutral ratings and others, such as JPMorgan at US$12, keeping a more cautious stance. As you read on, you will see how these shifting targets feed into the broader narrative around risk, execution, and what to watch next with...

The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because analysts typically say nice things about companies so their firms can win business in other product lines like M&A advisory.

Shares of healthcare diagnostics company QuidelOrtho (NASDAQ:QDEL) fell 21.3% in the afternoon session after the company slashed its full-year revenue and earnings forecast, overshadowing a second-quarter earnings beat.